Blood Res.  2018 Mar;53(1):90-92. 10.5045/br.2018.53.1.90.

Cancer associated phlegmasia cerulea dolens successfully treated with apixaban

• García-Fernández-Bravo I
• Demelo-Rodríguez P
• Ordieres-Ortega L
• Álvarez-Luque A
• Del Toro-Cervera J

• KMID: 2414373
• DOI: http://doi.org/10.5045/br.2018.53.1.90

Abstract

No abstract available.

Figure

• 

  Fig. 1 Swelling and cyanosis in the left lower limb characteristic of phlegmasia cerulea dolens (A). Evolution after 6 months (B).

• 

  Fig. 2 Computerized tomography phlebography revealing deep vein thrombosis in the left iliac vein (red arrow).

Reference

1. Perkins JM, Magee TR, Galland RB. Phlegmasia caerulea dolens and venous gangrene. Br J Surg. 1996; 83:19–23.

2. Galanaud JP, Sevestre-Pietri MA, Bosson JL, et al. Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: results from the OPTIMEV study. Thromb Haemost. 2009; 102:493–500.

3. Mumoli N, Invernizzi C, Luschi R, Carmignani G, Camaiti A, Cei M. Phlegmasia cerulea dolens. Circulation. 2012; 125:1056–1057.

4. Tung CS, Soliman PT, Wallace MJ, Wolf JK, Bodurka DC. Successful catheter-directed venous thrombolysis in phlegmasia cerulea dolens. Gynecol Oncol. 2007; 107:140–142.

5. Schweizer J, Kirch W, Koch R, et al. Short- and long-term results after thrombolytic treatment of deep venous thrombosis. J Am Coll Cardiol. 2000; 36:1336–1343.

6. Fahrni J, Engelberger RP, Kucher N, Willenberg T, Baumgartner I. Catheter-based treatment of ilio-femoral deep vein thrombosis - an update on current evidence. Vasa. 2013; 42:161–167.

7. Casey ET, Murad MH, Zumaeta-Garcia M, et al. Treatment of acute iliofemoral deep vein thrombosis. J Vasc Surg. 2012; 55:1463–1473.

8. Meissner MH, Gloviczki P, Comerota AJ, et al. Early thrombus removal strategies for acute deep venous thrombosis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2012; 55:1449–1462.

9. Ross JA, Miller M, Hernandez CR. OC-13 - Safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism. Thromb Res. 2016; 140:Suppl 1. S173–S174.